aleniglipron
aleniglipron: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Structure Therapeutics Inc. (GPCR) | Phase 2 |
Clinical Trials (1)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight
FDA Decisions
Frequently asked questions
Who is developing aleniglipron?
aleniglipron is being developed by Structure Therapeutics Inc..
How many clinical trials involve aleniglipron?
BioSniper tracks 1 clinical trial involving aleniglipron.
What is aleniglipron's latest FDA decision?
The most recent tracked FDA decision for aleniglipron is FDA_Meeting for Company plans to request a Type B End-of-Phase 2 meeting with the FDA in H1 2026 to finalize Phase 3 design (starting titration 2.5 mg; evaluate doses up to 240 mg)..
Get deeper analysis on aleniglipron
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis